New combo therapy aims to shrink tumors before surgery
NCT ID NCT05176002
Summary
This study is testing if adding an immunotherapy drug (camrelizumab) to standard radiation helps shrink tumors before surgery for esophageal cancer. It involves 25 adults with a specific type of operable esophageal cancer who have not had prior treatment. The main goals are to see if this combination is safe and if it leads to a significant reduction or complete disappearance of cancer cells in the surgically removed tissue.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIOTHERAPY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350001, China
Conditions
Explore the condition pages connected to this study.